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Background. Nonalcoholic fatty liver disease (NAFLD) is a leading cause of liver disease worldwide. Elevated sex hormone–
binding globulin (SHBG) levels have been observed in the setting of HIV and may protect against some metabolic disorders. We 
aimed to investigate whether higher SHBG levels may protect against NAFLD in men with/without HIV.
Methods. NAFLD was assessed using noncontrast computed tomography in 530 men in the Multicenter AIDS Cohort Study 
(MACS) who drank <3 alcoholic drinks/d and were uninfected with chronic hepatitis C or B (340HIV+, 190HIV-). Morning serum 
samples were tested for SHBG, total testosterone (TT), and adiponectin. Multivariable logistic regression was used to assess associ-
ations between HIV, SHBG, TT, adiponectin, and NAFLD.
Results. Median SHBG was highest among HIV+/NAFLD- men and lowest among HIV-/NAFLD+ men. Adjusted for demo-
graphics, HIV, visceral adiposity, HOMA-IR, TT, and PNPLA3 genotype, higher SHBG was associated with lower odds of NAFLD 
(odds ratio [OR], 0.52 per doubling; 95% confidence interval [CI], 0.34–0.80). In separate multivariable models without SHBG, 
HIV (OR, 0.46; 95% CI, 0.26–0.79) and higher adiponectin (OR, 0.66 per doubling; 95% CI, 0.49–0.89) were associated with lower 
NAFLD odds, whereas TT was not significantly associated (OR, 0.74 per doubling; 95% CI, 0.53–1.04). Adjusting for SHBG attenu-
ated the associations of HIV (OR, 0.61; 95% CI, 0.34–1.08) and adiponectin (OR, 0.74; 95% CI, 0.54–1.02) with NAFLD.
Conclusions. SHBG levels were higher among HIV+ men, were independently associated with lower NAFLD, and could par-
tially explain the associations of HIV and higher adiponectin with lower NAFLD in our cohort. These findings suggest that SHBG 
may protect against NAFLD, supporting further prospective and mechanistic studies.
Keywords. fatty liver; HIV; NAFLD; SHBG; testosterone.
Nonalcoholic fatty liver disease (NAFLD) is a leading cause of 
liver disease worldwide, with a global prevalence of 25% [1]. 
Associations of obesity, dyslipidemia, diabetes, and metabolic 
syndrome with NAFLD are well established [2]. Metabolic al-
terations are increasingly common among aging HIV-infected 
persons, and NAFLD is highly prevalent in this group, raising 
concerns that persons living with HIV infection are at increased 
risk of NAFLD [3, 4]. However, we previously found that HIV 
infection was associated with a lower odds of NAFLD among 
men who participated in the Multicenter AIDS Cohort Study 
(MACS) [5]. Similarly, in the Women’s Interagency HIV Study, 
HIV-infected women without viral hepatitis had significantly 
less liver fat than HIV-uninfected women [6]. The association 
of less liver fat with HIV infection in these studies was sur-
prising and was not altered after adjusting for multiple poten-
tial confounders. Recently, other cohort studies have similarly 
demonstrated lower rates of fatty liver in people living with HIV 
compared with those without HIV, for reasons that remain un-
clear [7, 8].
Sex hormone–binding globulin (SHBG) is a liver-derived 
protein that may have an important role in energy metab-
olism. Lower SHBG levels are associated with a higher prev-
alence of diabetes and metabolic syndrome [9, 10]. Although 
the mechanisms driving this relationship remain unclear, ex-
isting evidence suggests a causal role of SHBG in the develop-
ment of diabetes. Prospective studies show a protective effect 
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of higher SHBG against incident diabetes, and genetic studies 
demonstrate that carriers of single nucleotide polymorphisms 
in SHBG that raise SHBG levels have a lower risk of type 2 di-
abetes, whereas carriers of the SHBG-lowering allele have an 
increased risk [9, 11, 12]. Moreover, the relationship of SHBG 
with diabetes is bi-directional, as insulin inhibits hepatic SHBG 
production [13].
Studies performed to date in HIV-uninfected populations 
have similarly demonstrated lower circulating SHBG levels in 
patients with NAFLD, although the directionality of this asso-
ciation is unclear because SHBG is produced in the liver [14]. 
Low SHBG levels could be a consequence of NAFLD, as fat 
deposition in the liver may lead to downregulation of SHBG 
production [15]. However, preclinical models suggest that low 
SHBG could increase NAFLD risk, as overexpression of SHBG 
in mice causes decreased lipogenesis and is protective against 
NAFLD development [16]. Notably, HIV-infected men in the 
MACS have higher SHBG levels than HIV-uninfected men, de-
spite having more insulin resistance and diabetes [17]. Other 
studies have similarly observed elevated SHBG levels in associ-
ation with HIV infection, but the reasons for this are not under-
stood [18–20]. We hypothesized that higher SHBG levels may 
be protective against NAFLD and may explain the apparent 
protective association between HIV infection and NAFLD. We 
tested this hypothesis in the subset of MACS men previously 
evaluated for NAFLD [5].
METHODS
Study Design and Participants
We conducted a cross-sectional analysis within the MACS, an 
ongoing prospective cohort study of men who have sex with 
men. MACS participants were recruited from 4 sites in the 
United States (Baltimore, MD, USA/Washington DC, USA, 
Chicago, IL, USA, Pittsburgh, PA, USA, and Los Angeles, CA, 
USA). Details of study recruitment and participant character-
istics have been described elsewhere [21, 22]. Participants are 
followed semi-annually for interviews, physical examination, 
and laboratory testing. This analysis includes men who were 
enrolled in the MACS cardiovascular disease substudy and who 
underwent computed tomography (CT) imaging from January, 
2010, to August, 2013 [23]. Exclusion criteria for the cardiovas-
cular disease substudy were age <40 or >70 years, weight >300 
pounds, history of cardiac surgery, or history of coronary angio-
plasty or stent placement. For the current analysis, we addition-
ally excluded men who consumed an average of ≥3 alcoholic 
drinks per day, were chronically infected with hepatitis C virus 
(HCV) or hepatitis B virus, had incomplete visualization of 
the liver and spleen on noncontrast cardiac CT, did not have 
serum available for sex hormone testing, or were missing other 
key covariates (Supplementary Figure 1). Among the 603 men 
who met criteria for inclusion, 530 men had available morning 
serum samples for sex hormone measurement between 1 year 
before and 15 days after their CT scan date and were included 
in the final analysis.
Candidate covariates, including fasting serum insulin, glu-
cose, triglycerides, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), CD4+ T-cell count, and plasma HIV-1 
RNA levels, were obtained from the MACS visit most prox-
imal to the CT scan, as previously described [24]. Age, race, 
and medications were obtained through self-report. Body mass 
index (BMI) was calculated as body weight (kg)/height (m)2. 
Diabetes was defined as either fasting glucose ≥126 mg/dL or 
use of a diabetes medication. The homeostatic model assessment 
of insulin resistance (HOMA-IR) was natural log–transformed. 
Hypertension was defined as any of the following: systolic blood 
pressure (BP) >140 mmHg, diastolic BP >90 mmHg, or use of 
an antihypertensive medication. PNPLA3 (rs738409) genotype 
was determined in our prior study [5]. The study was approved 
by the local ethical committee at each MACS site, and all parti-
cipants signed informed consent.
Fatty Liver and Adipose Tissue Measurements
Fatty liver was defined as a liver/spleen Hounsfield unit ratio 
<1.0 on noncontrast CT scan, as previously described [5]. CT 
scans were reviewed by a single reader who was blinded to par-
ticipant demographic and clinical data. A single CT slice in the 
space between the fourth and fifth lumbar vertebrae was used 
to measure visceral adipose tissue (VAT) and subcutaneous ad-
ipose tissue (SAT) areas [25].
Sex Hormone and Adiponectin Measurements
All hormone assays were performed on morning serum sam-
ples stored at –80°C from the MACS visit closest to CT scan-
ning. Testing was performed on 334 samples in 2010 using 
the DELFIA immunofluorometric assay (Turku, Finland) and 
on the remaining 196 samples in 2017 using the Beckman 
Coulter Access Chemluminescent Immunoassay (Fullerton, 
CA, USA). Total testosterone (TT) levels were measured using 
liquid chromatography tandem mass spectrometry on all 530 
samples. Adiponectin levels were measured from serum sam-
ples stored at –80°C and collected at the time of CT scanning 
using enzyme-linked immunosorbent assay (R&D Systems, 
Minneapolis, MN, USA).
Statistical Analysis
We compared participant characterisitics by HIV serostatus 
using the chi-square test for categorical variables and the 
Wilcoxon rank-sum test for continuous variables. The Kruskal-
Wallis test was used to compare SHBG values across HIV and 
NAFLD categories. To determine if SHBG or TT was associated 
with NAFLD, multivariable logistic regression models with sex 
hormone levels as the primary predictors and NAFLD as the out-
come were constructed in a sequential fashion: adjusted for age, 
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race, MACS site, test batch (to adjust for the 2 different SHBG 
assays), HIV serostatus, PNPLA3 genotype (base model), base 
model + VAT area, and base model + VAT area + HOMA-IR. 
The model covariates were selected based on our prior analyses 
of factors associated with NAFLD in the cohort [5, 24]. SHBG 
and TT levels were log2-transformed and were first evaluated in-
dividually in the regression models and then included jointly in 
the models. The final model included both SHBG and TT levels 
after formally assessing for multicollinearity using the variance 
inflation factor, which was within the acceptable range [26]. We 
repeated the analysis stratified by HIV serostatus to determine 
whether the observed relationship of SHBG levels with NAFLD 
differed by HIV serostatus. To determine whether adjustment 
for SHBG levels attenuates the magnitude of the association 
of HIV infection with NAFLD, we used a base model that ad-
justed for HIV serostatus, age, race, MACS site, test batch, and 
PNPLA3 genotype and evaluated HIV serostatus as the primary 
predictor with and without SHBG in the model. Finally, we re-
peated this process, adding adiponectin levels (which we previ-
ously found to be inversely associated with NAFLD regardless 
of HIV serostatus [24]) or TT to the base model with/without 
SHBG. Statistical analyses were performed using Stata/SE, ver-
sion 13.1 (StataCorp, College Station, TX, USA), and R, ver-
sion 3.3.2 (The R Foundation for Statistical Computing, Vienna, 
Austria).
RESULTS
Study Population
Compared with the 190 HIV-uninfected men, the 340 HIV-
infected men were slightly younger and had a lower median 
SAT area and median BMI but a similar median VAT area 
(Table 1). The HIV-infected men also had lower high-density 
lipoprotein cholesterol levels, higher triglyceride levels, and 
higher ALT and AST levels compared with the HIV-uninfected 
men. Median SHBG and median TT levels were significantly 
higher among HIV-infected compared with HIV-uninfected 
men. Median adiponectin levels were lower in the HIV-infected 
compared with HIV-uninfected men, but this was not statis-
tically significant. The HIV-infected men had lower NAFLD 
prevalence compared with HIV-uninfected men (15% vs 21%; 
P = .086).
Table 1. Characteristics of the Study Population
Characteristic HIV-Infected (n = 340), Median (IQR) or No. (%) HIV-Uninfected (n = 190), Median (IQR) or No. (%)
Age, y 52 (48–57) 54 (50–62)
Race   
 White non-Hispanic 195 (57) 127 (67)
 Black non-Hispanic 104 (31) 43 (23)
 Other 41 (12) 20 (11)
BMI, kg/m2 26 (23–29) 27 (24–30)
Abdominal VAT, mm2 150 (88–218) 148 (92–212)
Abdominal SAT, mm2 179 (114–265) 226 (163–304)
Diabetes 37 (11) 20 (11)
HOMA-IR 3.2 (2.2–4.9) 3.0 (2.2–4.2)
On lipid-lowering agent 129 (39) 60 (32)
HDL cholesterol, mg/dL 46 (37–54) 48 (41–58)
LDL cholesterol, mg/dL 107 (85–136) 110 (90–134)
Triglycerides, mg/dL 131 (93–205) 107 (77–154)
Hypertension 160 (49) 78 (43)
ALT, U/L 25 (19–35) 22 (17–28)
AST, U/L 23 (20–31) 22 (18–25)
APRI >1.5 3 (1) 0 (0)
FIB-4 >3.25 9 (3) 0 (0)
PNPLA3 non-CC genotype 138 (41) 89 (47)
NAFLD on CT scan 50 (15) 39 (21)
Adiponectin 5984 (3684–9725) 6539 (4444–9491)
SHBG 53 (36–71) 39 (28–52)
Total testosterone 588 (432–767) 474 (355–666)
Recent viral load <50 copies/mL 283 (83)  
Recent CD4+ T-cell count, cells/µL 597 (438–779)  
Cumulative HAART, y 9 (6–12)  
Bold formatting signifies statistical significance at P < .05.
Abbreviations: ALT, alanine aminotransferase; APRI, aspartate aminotransferase to platelet ratio index; AST, aspartate aminotransferase; BMI, body mass index; FIB-4, fibrosis-4 index; 
HAART, highly active antiretroviral therapy; HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment of insulin resistance; IQR, interquartile range; LDL, low-density lipopro-
tein; NAFLD, nonalcoholic fatty liver disease; SAT, subcutaneous adipose tissue; SHBG, sex hormone–binding globulin; VAT, visceral adipose tissue.
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SHBG But Not Total Testosterone Is Associated With Lower NAFLD
SHBG levels were highest among HIV-infected men without 
NAFLD, followed by HIV-uninfected men without NAFLD, 
and were lowest among men with NAFLD regardless of HIV 
serostatus (Figure 1). Median SHBG values among the 334 
men with measurement using the DELFIA assay were HIV+/
NAFLD- 60.0  nmol/L, HIV-/NAFLD- 46.2  nmol/L, HIV+/
NAFLD+ 38.0  nmol/L, and HIV-/NAFLD+ 38.8  nmol/L 
(P < .001). Median SHBG values among the 196 men with meas-
urement using the Beckman Coulter assay were HIV+/NAFLD- 
47.4  nmol/L, HIV-/NAFLD- 35.3  nmol/L, HIV+/NAFLD+ 
28.5 nmol/L, and HIV-/NAFLD+ 21.3 nmol/L (P <  .001). TT 
and SHBG levels were positively correlated with each other 
(Spearman rho correlation coefficient = .52; P < .001). Hence, 
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Figure 1. SHBG levels by HIV serostatus and NAFLD status. A, SHBG measured using the DELFIA assay. B, SHBG measured using the Beckman Coulter assay. Abbreviations: 
FL, fatty liver; SHBG, sex hormone–binding globulin.
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the pattern of TT level distribution after stratifying by HIV and 
NAFLD status was similar to that observed with SHBG (data 
not shown).
In multivariable analysis, higher SHBG levels were associated 
with lower odds of NAFLD (OR, 0.38 per SHBG doubling; 95% 
confidence interval [CI], 0.26–0.56) (Table 2). This association 
was attenuated but remained significant after further adjusting 
for VAT and HOMA-IR (OR, 0.52; 95% CI, 0.34–0.80). The ad-
dition of BMI to the model did not change the association. To 
determine if the association was independent of TT, the model 
including VAT and HOMA-IR was run excluding TT, and the 
association of SHBG with lower NAFLD remained (OR, 0.50; 
95% CI, 0.34–0.75). Notably, TT levels were not associated 
with NAFLD in any model, including a model with VAT and 
HOMA-IR (OR, 0.93; 95% CI, 0.63–1.36) (Table 2), and even 
in a model excluding SHBG (OR, 0.74; 95% CI, 0.52–1.04) 
(Table  3). These analyses were repeated stratified by HIV 
serostatus. The relationship of SHBG with NAFLD was similar 
between the groups, and likewise, we did not find an association 
of TT levels with NAFLD (Supplementary Table 1).
Adjusting for SHBG Attenuates the Association of HIV and NAFLD
After adjusting for age, race, MACS site, testing batch, PNPLA3 
genotype, VAT area, and HOMA-IR, HIV serostatus was as-
sociated with lower prevalence of NAFLD (OR, 0.46; 95% CI, 
0.26–0.79), consistent with our prior analysis (Table 3) [5]. 
Interestingly, after adjustment for SHBG levels, HIV infection 
was no longer significantly associated with lower NAFLD odds 
(OR, 0.61; 95% CI, 0.34–1.08), whereas associations of VAT, 
HOMA-IR, black race, and PNPLA3 non-CC genotype with 
NAFLD were unchanged (Table 2).
Adjusting for SHBG Adjustment Attenuates the Association of Adiponectin 
and NAFLD
We previously found an inverse relationship between levels of 
adiponectin, an adipokine involved in modulating glucose and 
lipid metabolism, and NAFLD in our cohort, regardless of HIV 
serostatus [24]. In the present analysis, we again found that 
higher levels of adiponectin were associated with lower NAFLD 
odds in a multivariable analysis (OR, 0.66 per doubling; 95% CI, 
0.49–0.89) (Table 3). This association was no longer statistically 
significant after further adjusting for SHBG levels (OR, 0.74; 
95% CI, 0.54–1.02). However, higher levels of SHBG remained 
independently associated with lower NAFLD odds even after 
adding adiponectin to the model (OR, 0.50 and 0.56 with and 
without adiponectin, respectively) (Table 3).
DISCUSSION
In this study of 530 well-characterized men with or at risk for 
HIV infection, higher SHBG levels were associated with lower 
odds of NAFLD after adjusting for known metabolic and ge-
netic risk factors, as well as for levels of TT and adiponectin. 
This finding was consistent regardless of HIV serostatus. 
Further, SHBG levels may explain, at least in part, the observed 
association between HIV and less NAFLD in our cohort, as this 
association was attenuated after accounting for SHBG levels.
SHBG is a protein produced in the liver that binds testos-
terone and other sex hormones and regulates their bioavailabilty 
[27]. SHBG may also have functions beyond transporting sex 
hormones, including maintaining metabolic homeostasis [28]. 
To our knowledge, this study is the first to evaluate the asso-
ciation of SHBG levels with NAFLD in the setting of HIV in-
fection. Our finding of an inverse relationship between SHBG 
levels and NAFLD has been reported previously in studies of 
HIV-uninfected persons. In a meta-analysis of 5 studies con-
ducted among HIV-uninfected men, high SHBG levels were as-
sociated with decreased NAFLD odds (pooled OR, 0.35; 95% 
CI, 0.25–0.45) [14]. SHBG levels have also been inversely asso-
ciated with metabolic perturbations that are linked to NAFLD, 
including insulin resistance, diabetes, and central adiposity 
[17, 29, 30]. Notably, in our current report, higher SHBG levels 
Table 2. Association Between SHBG Levels and NAFLD
Model 1a Model 1a + Visceral Adiposity
Model 1a + Visceral Adiposity + 
HOMA-IR
 Odds Ratio (95% CI) P Odds Ratio (95% CI) P Odds Ratio (95% CI) P
Log2 (SHBG) 0.38 (0.26–0.56) <.001 0.50 (0.33–0.77) .001 0.52 (0.34–0.80) .003
Log2 (TT) 0.75 (0.53–1.07) .12 0.87 (0.60–1.25) .44 0.93 (0.63–1.36) .70
HIV infection 0.93 (0.55–1.58) .80 0.65 (0.37–1.15) .14 0.61 (0.34–1.09) .10
VAT (per 10 mm2)   1.07 (1.04–1.11) <.001 1.05 (1.02–1.09) .002
Ln (HOMA-IR)     1.91 (1.17–3.11) .01
Age (per year) 1.00 (0.96–1.04) .82 0.97 (0.93–1.01) .14 0.97 (0.93–1.01) .13
Black race 0.26 (0.12–0.54) <.001 0.42 (0.19–0.92) .03 0.34 (0.15–0.77) .01
PNPLA3 non-CC 1.81 (1.10–2.98) .02 2.03 (1.20–3.41) .01 2.17 (1.28–3.68) .004
Bold formatting signifies statistical significance at P < .05.
Abbreviations: CI, confidence interval; HOMA-IR, homeostatic model assessment of insulin resistance; NAFLD, nonalcoholic fatty liver disease; SHBG, sex hormone–binding globulin; TT, 
total testosterone; VAT, visceral adipose tissue.
aAlso adjusted for MACS sites and test batch.
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remained strongly associated with lower odds of NAFLD, even 
after adjusting for HOMA-IR and VAT area. Hence, our ob-
served association of SHBG levels with NAFLD is unlikely to 
be a result of residual confounding exerted by metabolic factors.
Although associations of higher SHBG levels with decreased 
NAFLD could be due to reduced hepatic production of SHBG 
in the presence of liver fat [15, 31, 32], there are several lines of 
evidence supporting the assertion that SHBG actually protects 
against NAFLD. First, adiponectin, which is one of the most 
important adipokines as it regulates body weight, insulin sen-
sitivity, and inflammatory status [33, 34], was no longer associ-
ated with NAFLD after accounting for SHBG levels. In contrast, 
the SHBG association with NAFLD remained, independent of 
adiponectin levels; this suggests that SHBG mediates the protec-
tive effect of adiponectin on NAFLD. Second, recent evidence 
suggests that SHBG levels protect against NAFLD develop-
ment by modulating lipogenesis. In genetic and diet-induced 
NAFLD mouse models, overexpression of SHBG leads to sig-
nificant reductions in liver fat by downregulating key lipogenic 
enzymes [16]. Similarly, treatment with exogenous SHBG in 
vitro inhibits lipogenesis by decreasing PPAR-γ levels, whereas 
underexpression of SHBG results in increased hepatic lipogen-
esis [16]. Third, single nucleotide polymorphisms in SHBG that 
downregulate SHBG levels are associated with development of 
type 2 diabetes, suggesting that SHBG is causal [11]. Fourth, 
a study examining gene expression pathways from 72 liver 
samples from persons with NAFLD identified SHBG as 1 of 5 
leading candidates for affecting NAFLD development [35].
It is possible that the observed relationship of SHBG and 
NAFLD is due to testosterone rather than SHBG. However, TT 
levels were only weakly associated with NAFLD in our study, 
and adjusting for SHBG levels further weakened the association. 
Although a meta-analysis of 10 studies found an inverse rela-
tionship between TT levels and NAFLD among HIV-uninfected 
men [14], the analysis did not evaluate the combined asso-
ciations of SHBG and TT levels with NAFLD. One study re-
ported an inverse association of TT and NAFLD in unadjusted 
analysis that was diminished after adjusting for other NAFLD 
risk factors and SHBG [36]. Another study directly measured 
free testosterone (FT) and SHBG and found a strong inverse 
association between SHBG and NAFLD but failed to find an 
association between FT and NAFLD [37]. Finally, the protec-
tive effect of SHBG against NAFLD development persists in 
castrated mouse models, supporting our findings that TT is not 
driving the association of SHBG with NAFLD [16]. We were 
unable to assess the independent relationship between FT levels 
and NAFLD in this study because FT was not directly measured 
but rather calculated based on TT and SHBG levels. In addition, 
~9% of the men in our cohort were on testosterone supplemen-
tation. Thus, it is unclear whether our findings are generalizable 
to people with hypogonadism.
Despite the adverse metabolic effects of HIV infection and 
some antiretroviral medications, our prior analysis of MACS 
men unexpectedly found a protective association between HIV 
infection and prevalent NAFLD [5], a finding that is repro-
duced in the subset of men included in this analysis. We now 
further demonstrate that SHBG may partially mediate this pro-
tective association between HIV infection and NAFLD, as HIV 
infection was no longer significantly associated with protection 
from NAFLD after accounting for SHBG levels. Further work 
is needed to ascertain the mechanisms by which HIV infec-
tion may increase SHBG levels. Interestingly, patients with ac-
tive HCV also have elevated SHBG levels, which decline after 
achievement of sustained virologic response (SVR) with HCV 
treatment [38]. In a Canadian prospective cohort study, hepatic 
steatosis progressed faster in HIV-monoinfected patients com-
pared with HIV/HCV-coinfected patients, and in another co-
hort of adults with and without HIV and HCV, non–genotype 
3 HCV was independently associated with less liver fat despite 
adjustment for multiple factors, including liver fibrosis [39, 40]. 
It is intriguing to consider whether SHBG may mediate the as-
sociation of active HCV with less hepatic steatosis and whether 
the post-SVR decline in SHBG may affect a patient’s risk of de-
veloping NAFLD after SVR.
The major strengths of our study were the large sample size 
with comprehensive assessments of multiple NAFLD risk fac-
tors, such as visceral adiposity, insulin resistance, and PNPLA3, 
and the inclusion of an HIV-uninfected comparator group. 
However, a major limitation is that we were unable to as-
sess the directionality of the relationship between SHBG and 
NAFLD because of the cross-sectional design. Another limita-
tion was the reliance on noncontrast CT to diagnose fatty liver; 
noncontrast CT will detect moderate or greater amounts of 
liver fat but is less sensitive to detect mild fatty liver. We also 
do not have nonfasting measures of insulin resistance in our 
cohort and therefore could not assess whether insulin levels 
Table 3. Association of HIV Infection, Total Testosterone Levels, and 
Adiponectin Levels With NAFLD, With and Without Adjustment for SHBG 
Levels
Odds Ratio (95% CI)
 Without SHBGa With SHBG
Log2 (SHBG) – 0.52 (0.34–0.80)
Log2 (TT) 0.74 (0.53–1.04) 0.93 (0.63–1.36)
Log2 (SHBG) – 0.50 (0.34–0.75)
HIV infection 0.46 (0.26–0.79) 0.61 (0.34–1.08)
Log2 (SHBG) – 0.56 (0.37–0.85)
Log2 (Adiponectin) 0.66 (0.49–0.89) 0.74 (0.54–1.02)
Bold formatting signifies statistical significance at P < .05.
Abbreviations: CI, confidence interval; HOMA-IR, homeostatic model assessment of in-
sulin resistance; NAFLD, nonalcoholic fatty liver disease; SHBG, sex hormone–binding 
globulin; TT, total testosterone; VAT, visceral adipose tissue.
aBase model includes HIV serostatus, age, race, MACS site, testing batch, PNPLA3 gen-
otype, VAT, and HOMA-IR. TT and adiponectin were each evaluated separately in the 
multivariable models.
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throughout the day affect the association of SHBG and NAFLD. 
In addition, the MACS is comprised only of men, and therefore 
our findings may not be generalizable to women living with or 
at risk for HIV infection. This is especially important because 
the association of sex hormones and NAFLD appears to differ 
by sex [14]. Finally, we did not have liver biopsies available and 
were therefore unable to evaluate whether SHBG levels corre-
late with histologic severity of liver disease in our cohort. This is 
important because HIV-infected individuals with NAFLD may 
have an elevated risk of nonalcoholic steatohepatitis and fibrosis 
[4, 41].
In conclusion, we found that among men living with or at 
risk for HIV infection, SHBG levels were inversely associated 
with NAFLD regardless of HIV serostatus. SHBG levels were 
higher among HIV-infected men regardless of the presence of 
NAFLD, and adjustment for SHBG levels attenuated the asso-
ciation of HIV infection with lower odds of NAFLD. The un-
derlying mechanisms driving elevations in SHBG levels among 
HIV-infected persons remain unclear and warrant further in-
vestigation. Our findings also support prospective evaluation 
of the relationship of SHBG and NAFLD and translational re-
search focused on potential mechanisms by which SHBG may 
influence NAFLD development and progression. Finally, fur-
ther work is needed to determine the relationship of SHBG, 
HCV, and NAFLD.
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the posted materials are not copyedited and are the sole responsibility of 
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